Tanja Obradovic, Therapeutic Strategy Lead of Oncology at Novotech, Senior Advisor of Oncology Drug Development at HopeAI, shared a post on LinkedIn:
“With powerful multimodal artificial intelligence analytical platform made on high-quality curated mega-size data sets, HopeAI is focused on working with Pharma and Biotech companies aiming to perform customized study phase, indication, and treatment-line study design assumptions, discover optimal patient populations to derive treatment benefit, identify critical biomarker elements, and validate control group assumptions.
The goal is to design oncology clinical trials with optimized size and end points and an increased probability of regulatory success.
Expecting a productive discussion as one of the panelists at this roundtable at ASCO 2026: ‘From Trial Design and Development Decisions to Regulatory Success.’
Registration to the roundtable and dinner event.”
Other articles about ASCO on OncoDaily.